Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

USA - NASDAQ:CADL - US1374041093 - Common Stock

4.64 USD
+0.03 (+0.65%)
Last: 11/14/2025, 5:32:17 PM
4.61 USD
-0.03 (-0.65%)
After Hours: 11/14/2025, 5:32:17 PM
Fundamental Rating

2

Taking everything into account, CADL scores 2 out of 10 in our fundamental rating. CADL was compared to 531 industry peers in the Biotechnology industry. The financial health of CADL is average, but there are quite some concerns on its profitability. CADL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CADL has reported negative net income.
CADL had a negative operating cash flow in the past year.
CADL had negative earnings in each of the past 5 years.
CADL had a negative operating cash flow in each of the past 5 years.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.89%, CADL is in the better half of the industry, outperforming 74.95% of the companies in the same industry.
The Return On Equity of CADL (-24.54%) is better than 80.60% of its industry peers.
Industry RankSector Rank
ROA -20.89%
ROE -24.54%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for CADL has been increased compared to 1 year ago.
Compared to 5 years ago, CADL has more shares outstanding
CADL has a better debt/assets ratio than last year.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CADL has an Altman-Z score of 7.01. This indicates that CADL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CADL (7.01) is better than 78.53% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CADL is not too dependend on debt financing.
CADL has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 7.01
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 7.04 indicates that CADL has no problem at all paying its short term obligations.
The Current ratio of CADL (7.04) is better than 70.24% of its industry peers.
A Quick Ratio of 7.04 indicates that CADL has no problem at all paying its short term obligations.
The Quick ratio of CADL (7.04) is better than 70.43% of its industry peers.
Industry RankSector Rank
Current Ratio 7.04
Quick Ratio 7.04
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CADL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.27%, which is quite impressive.
EPS 1Y (TTM)59.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.41% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.64%
EPS Next 2Y15.92%
EPS Next 3Y19.41%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CADL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CADL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

CADL's earnings are expected to grow with 19.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.92%
EPS Next 3Y19.41%

More info and screens

0

5. Dividend

5.1 Amount

CADL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (11/14/2025, 5:32:17 PM)

After market: 4.61 -0.03 (-0.65%)

4.64

+0.03 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06
Earnings (Next)03-23 2026-03-23/amc
Inst Owners42.29%
Inst Owner Change-7.04%
Ins Owners15.75%
Ins Owner Change2.33%
Market Cap254.74M
Revenue(TTM)N/A
Net Income(TTM)-22.14M
Analysts82.86
Price Target19.38 (317.67%)
Short Float %16.63%
Short Ratio9.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.29%
Min EPS beat(2)48.1%
Max EPS beat(2)142.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.39%
PT rev (3m)-9.52%
EPS NQ rev (1m)-2.29%
EPS NQ rev (3m)22.08%
EPS NY rev (1m)-118.01%
EPS NY rev (3m)5.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS1.64
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.89%
ROE -24.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.04
Quick Ratio 7.04
Altman-Z 7.01
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.42%
EPS Next Y73.64%
EPS Next 2Y15.92%
EPS Next 3Y19.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.1%
EBIT Next 3Y-2.14%
EBIT Next 5Y83.63%
FCF growth 1Y14.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.8%
OCF growth 3YN/A
OCF growth 5YN/A

CANDEL THERAPEUTICS INC / CADL FAQ

Can you provide the ChartMill fundamental rating for CANDEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CADL.


What is the valuation status for CADL stock?

ChartMill assigns a valuation rating of 0 / 10 to CANDEL THERAPEUTICS INC (CADL). This can be considered as Overvalued.


How profitable is CANDEL THERAPEUTICS INC (CADL) stock?

CANDEL THERAPEUTICS INC (CADL) has a profitability rating of 1 / 10.


Can you provide the financial health for CADL stock?

The financial health rating of CANDEL THERAPEUTICS INC (CADL) is 5 / 10.